Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
US-2024216388-A1 · Jul 4, 2024 · US
US10435673B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10435673-B2 |
| Application number | US-201515514120-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 27, 2015 |
| Priority date | Oct 3, 2014 |
| Publication date | Oct 8, 2019 |
| Grant date | Oct 8, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method is proposed for producing flavonoids, comprising the steps: (a) providing of a transgenic microorganism, containing (i) a first nucleic acid section (A), comprising or consisting of a gene coding for a CYP450 oxidase, (ii) a second nucleic acid section (B), comprising or consisting of a gene coding for a plant O-methyltransferase, and (b) adding of one or more flavanones to the transgenic microorganism, (c) the conversion of the substrate flavanones by the transgenic microorganism to the corresponding flavonoids, and optionally (d) isolating and purifying of the final products.
Opening claim text (preview).
The invention claimed is: 1. A process for the production of flavonoids, comprising: (a) adding one or more flavanones selected from naringenin and naringin to a transgenic microorganism, the transgenic microorganism comprising a first nucleic acid segment (A), comprising the nucleotide sequence set forth as SEQ ID NO:1 and/or the nucleotide sequence set forth as SEQ ID NO:2 and/or a nucleotide sequence at least 95% identical to SEQ ID NO:1 and/or SEQ ID NO:2 and which codes for a CYP450 oxidase that catalyzes the conversion of naringenin to eriodictyol and which comprises A75G, F88V, L189Q, and R472C amino acid substitutions and/or comprises A75G, F88V, L189Q, A331S and R472C amino acid substitutions, the numbering of amino acid residues being in accordance with that of SEQ ID NO:6, and a second nucleic acid segment (B), comprising a gene having the nucleotide sequence set forth as SEQ ID NO:3 or having a nucleotide sequence at least 95% identical to the nucleotide sequence set forth as SEQ ID NO:3 and which codes for a plant O-methyltransferase that catalyzes the conversion of eriodictyol to hesperetin, whereby the flavanones naringenin and/or naringin are converted to the corresponding flavonoid(s) eriodictyol, homoeriodictyol, hesperetin, sterubin, apigenin, luteolin, diosmetin, and/or chryseriol by the transgenic microorganism, and optionally (b) isolating and purifying the end products. 2. An enzymatic process for the production of flavonoids, comprising the following steps: (a) providing (i) a first CP450 oxidase enzyme that catalyzes the conversion of naringenin to eriodictyol and which comprises A75G, F88V, L189Q, and R472C amino acid substitutions and/or comprises A75G, F88V, L189Q, A331S and R472C amino acid substitutions, the numbering of amino acid residues being in accordance with that of SEQ ID NO:6, and (ii) a second plant O-methyltransferase enzyme encoded by a gene having the nucleotide sequence set forth as SEQ ID NO:3 or a sequence at least 95% identical to the nucleotide sequence set forth as SEQ ID NO:3 and which catalyzes the conversion of eriodictyol to hesperetin, (b) adding one or more flavanones selected from naringenin and naringin to the reaction of (a), (c) converting the flavanones naringenin and/or naringin to the corresponding flavonoid(s) eriodictyol, homoeriodictyol, hesperetin, sterubin, apigenin, luteolin, diosmetin, and/or chryseriol by first and/or the second enzyme, and optionally (d) isolating and purifying the end products. 3. The process of claim 1 , wherein the transgenic microorganism comprises a first nucleic acid segment (A), comprising the nucleotide sequence set forth as SEQ ID NO:1 and/or the nucleotide sequence set forth as SEQ ID NO:2 and a second nucleic acid segment (B), comprising a gene coding for a plant O-methyltransferase having the nucleotide sequence set forth as SEQ ID NO:3. 4. The process of claim 1 , wherein the gene coding for a bacterial CYP450 oxidase codes for an oxidase from the microorganism Bacillus megaterium. 5. The process of claim 1 , wherein the gene coding for a plant O-methyltransferase codes for an O-methyltransferase from the plant genus Mesembryanthemum. 6. The process of claim 1 , wherein the microorganism is a facultatively anaerobic microorganism.
Methyltransferases (general) (2.1.1.) · CPC title
Methyltransferases (2.1.1) · CPC title
acting on paired donors with incorporation of molecular oxygen (1.14) · CPC title
Unspecific monooxygenase (1.14.14.1) · CPC title
containing a six-membered hetero ring, e.g. fluorescein · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.